Hemophilia B (Factor IX Deficiency) - Pipeline Review, H2 2019

Hemophilia B (Factor IX Deficiency) - Pipeline Review, H2 2019



Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2019, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 9, 6, 2, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction
Hemophilia B (Factor IX Deficiency) - Overview
Hemophilia B (Factor IX Deficiency) - Therapeutics Development
Hemophilia B (Factor IX Deficiency) - Therapeutics Assessment
Hemophilia B (Factor IX Deficiency) - Companies Involved in Therapeutics Development
Hemophilia B (Factor IX Deficiency) - Drug Profiles
Hemophilia B (Factor IX Deficiency) - Dormant Projects
Hemophilia B (Factor IX Deficiency) - Discontinued Products
Hemophilia B (Factor IX Deficiency) - Product Development Milestones
Appendix

List Of Tables

Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by ApcinteX Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by ASC Therapeutics Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Catalyst Biosciences Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by China Biologic Products Holdings Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Expression Therapeutics LLC, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Freeline Therapeutics Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by GC Pharma, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Genzyme Corp, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Intellia Therapeutics Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by LFB SA, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Logicbio Therapeutics Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Novo Nordisk AS, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by OPKO Biologics Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Pfizer Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by RegenxBio Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Sangamo Therapeutics Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Sanofi, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Shenzhen Weiwu Guangming Biological Preparations Co Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Sigilon Therapeutics Inc, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Hemophilia B (Factor IX Deficiency) - Pipeline by UniQure NV, H2 2019
Hemophilia B (Factor IX Deficiency) - Dormant Projects, H2 2019
Hemophilia B (Factor IX Deficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Hemophilia B (Factor IX Deficiency) - Discontinued Products, H2 2019

List Of Figures

Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available